Thus, further characterization of the precise mechanisms by which CPA induces susceptibility to TRAIL-mediated apoptosis may aid with the development of agents possessing greater long-term efficacy for the treatment of CR prostate cancer. The gene discussed is TNFSF10; the disease is prostate carcinoma.